Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
20h
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...
GlobalData on MSN21h
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapyRegenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...
The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback